ICYMI, this week we had stories about atopic dermatitis, acne, psoriasis, consumer trends, and more.
At an SPD 2022 47th Annual Meeting poster session, researchers look at gender and age differences in pediatric patients with melanoma.
Precision medicine offers better results while treating severe atopic dermatitis.
A recent acne vulgaris study used high-frequency ultrasonography (HF-USG) and power Doppler (PD) to assess the thickness of lesions.
Click here to answer this week's poll.
This week's edition of the Mainstream Patient features stories about dermaplaning tools, pregnancy-safe sunscreens, botox, and more.
Additional research is required to determine the content validity of patient-reported outcome measures from patients with acne.
At the SPD 2022 47th Annual Meeting, we chat with Albert Yan, MD, of Children's Hospital of Philadelphia on the latest trends in technology for pediatric dermatologists.
In this epsiode, Raj Chovatiya, MD, PhD, discusses the changing field of atopic dermatitis, the importance of JAK inhibitors, and the treatment options he looks forward to.
The increases had no impact on the efficacy of the drug and were rarely associated with symptoms or sequelae.
A better understanding of this atopic diathesis and the atopic march often seen in pediatric patients is necessary to optimally treat and manage the patient population, ideally in a multidisciplinary setting.
A study published in JAAD International examined the association between psoriasis and adverse pregnancy outcomes (APOs) and found that providers should be on the lookout for ectopic pregnancies (EP) in this population.
Paller discusses the findings of the clinical trial examining the long-term effects of ixekizumab for treating psoriasis in children.
Perimenopausal, menopausal, and postmenopausal women experienced a progressive improvement in hair growth, shedding, quality of life, and menopausal symptoms after 12 months with an active nutraceutical supplement.
The groundbreaking approval of sirolimus topical gel brings relief to patients with facial angiofibroma related to tuberous sclerosis complex with the first FDA-approved topical treatment.
Investigators suggest parents and clinicians should be mindful of children with suspected ACD with a history of exposure to jewelry, clothing, and belts with cobalt.